血小板抗体检测及配型在肿瘤患者中的临床应用

发布时间：2018-05-30 01:31

本文选题：血小板抗体 + 交叉配型　；参考：《中国输血杂志》2016年07期

【摘要】：目的通过检测肿瘤患者血清中的血小板抗体及其血小板配型,对比随机输注组患者和相合输注组患者的血小板治疗效果,进一步评估此方法的临床意义。方法应用固相凝聚法对2011年1月-2015年1月期间在我院住院需要输注血小板的460例肿瘤患者血清标本进行血小板抗体检测,共检出血小板抗体阳性者58例,阳性率为12.6%(58/460)。其中,将58例血小板抗体阳性的肿瘤患者按照血小板输注方式分为两组:实验组采用血小板配型相合后再进行血小板输注共98次,随机输注组直接进行血小板输注共138次,回顾性分析比较两组患者血小板输注前后1h、24h血小板计数增高指数(CCI)、血小板恢复百分率(PPR)以及血小板有效输注之间的差异。结果两组患者在血小板输注前1h,其血小板计数比较无统计学意义(P0.05)。随机输注组患者与相合输注组患者输注血小板1h、24h后,其CCI和PPR相比较,差异有统计学意义(P0.01)。结论对肿瘤患者进行血小板抗体检测和配型,进一步了解患者体内血小板抗体产生的情况,有效的改善了肿瘤患者血小板输注无效症状,同时提高了血小板输注的疗效,避免了血小板输注无效而引起患者病情加重恶化和血小板滥用等情况,从而保证了临床治疗效果。
[Abstract]:Objective to evaluate the clinical significance of this method by detecting platelet antibody and platelet matching in patients with tumor and comparing the effect of platelet therapy between random infusion group and matched transfusion group. Methods Platelet antibodies were detected by solid phase coagulation method in 460 tumor patients who were hospitalized in our hospital from January 2011 to January 2015. A total of 58 patients were found to be positive for platelet antibodies, the positive rate was 12.6%. Among them, 58 patients with platelet antibody positive tumor were divided into two groups according to platelet transfusion mode: the experimental group received platelet transfusion for 98 times after platelet matching, and the random transfusion group received a total of 138 platelet transfusions directly. The difference of platelet count increase index (CCI), platelet recovery percentage (PPRR) and effective platelet infusion between the two groups before and after platelet infusion was analyzed retrospectively. Results there was no significant difference in platelet count between the two groups at 1 hour before platelet transfusion (P 0.05). The CCI and PPR of the patients in the randomized infusion group and the matched infusion group were significantly higher than that of the control group (P 0.01). Conclusion Platelet antibody was detected and matched in patients with tumor, so as to understand the status of platelet antibody production in patients with tumor, effectively improve the symptoms of platelet transfusion in tumor patients, and improve the efficacy of platelet transfusion. It can avoid the deterioration of patients' condition and platelet abuse caused by invalid platelet transfusion, thus ensuring the effect of clinical treatment.
【作者单位】：第四军医大学西京医院输血科;
【分类号】：R457.1;R730.43

【相似文献】